Sharps Technology, Inc. STSS stock is trading higher on Wednesday.As per data from Benzinga Pro, session volume stands at 31.74 million versus an average volume of 674.72k.What Happened: The medical device and pharmaceutical packaging company initiated shipments for previously announced purchase orders across three customer orders.These shipments mark the company’s first deliveries of its SecureGard and SoloGard product lines and its transition to generating commercial revenue.“These initial shipments mark ...

PROCEPT BioRobotics (PRCT) FY Conference June 04, 2025 11:00 AM ET Speaker0 Hello? Sorry. Hi, everyone. My name is Brandon Vasquez. I am the analyst here at William Blair that covers Procept biorobotics. I am required to tell you and inform you to go to our website at williamblair.com a complete list of disclosures and conflicts of interests. With that said, happy to have president and CEO Reza Zadno with us. He's gonna run us through a company presentation before we go to our breakout. So with that, I'll t ...

Demographic Trends - The global population is aging rapidly, with life expectancies increasing and birth rates declining, leading to a demographic imbalance in both developed and emerging economies [1] - By 2030, one in six individuals globally will be over 60, and by 2050, this figure is expected to reach 2.1 billion, with 80% residing in low- and middle-income countries [2] Healthcare Market Dynamics - The global geriatric care market was valued at approximately $1.2 trillion in 2025, up from around $1 trillion in 2022, driven by the rising prevalence of chronic conditions among older adults [3] - There is a growing demand for pharmaceuticals, medical devices, home-based care, and digital health solutions tailored for aging populations [3] Company Strategies - Healthcare companies like Boston Scientific, AbbVie, Amgen, and Dexcom are enhancing operational efficiency to expand their presence in the Seniors & Aging Demographics domain [4] - Pharmaceutical companies are focusing on developing treatments for chronic conditions prevalent in older adults, particularly in immunology, oncology, and neurodegenerative diseases [5] Investment Opportunities - The Healthcare Real Estate Investment Trust (Healthcare REIT) sector is gaining attention, with companies like Community Healthcare Trust and CareTrust REIT focusing on specialized healthcare real estate for the aging population [6] - Digital health solutions, AI-driven diagnostics, and home-based monitoring systems are creating new revenue opportunities for healthcare firms [5] Company Highlights - Boston Scientific has developed devices like the WATCHMAN and SYNERGY systems, catering to the needs of elderly patients [8] - AbbVie is expanding its focus on the aging demographic through strategic acquisitions and partnerships, including the acquisition of Aliada Therapeutics for Alzheimer's treatment [10][11] - Amgen is advancing its R&D pipeline with a focus on elderly-targeted medicines, including osteoporosis treatments and obesity drugs [13][14][15] - Dexcom is enhancing its continuous glucose monitoring systems for seniors, including the launch of the Stelo system, which is designed for ease of use [16][17]

Penumbra (PEN) 2025 Conference June 04, 2025 09:55 AM ET Speaker0 Okay. So we're ready to kick off. This is the fireside chat with Penumbra. My name is Mike Sarcone. I'm one of the analysts on the US medical supplies and devices team. And with us from the company today, we have Adam El Seltzer. He's co founder, president, chairman, and CEO. We've also got Jason Mills, director of strategy. And Cecilia Furlong, who is a director of business Development, is also here with us. So team, thank you for joining us ...

Group 1: Zacks Premium Overview - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] - The service also includes Zacks Style Scores, which are designed to assist investors in selecting stocks with the highest potential to outperform the market in the short term [2] Group 2: Zacks Style Scores - Zacks Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each providing insights based on different investment strategies [3][4][5][6] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales [3] - The Growth Score evaluates a company's future earnings and financial health to identify stocks with sustainable growth potential [4] - The Momentum Score helps investors capitalize on price trends by analyzing recent price changes and earnings estimate revisions [5] - The VGM Score combines all three Style Scores to highlight stocks with the best value, growth, and momentum characteristics [6] Group 3: Zacks Rank and Style Scores Integration - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] - To maximize returns, investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 that also have Style Scores of A or B [9] - Stocks rated 4 (Sell) or 5 (Strong Sell) should be avoided, even if they have high Style Scores, due to declining earnings forecasts [10] Group 4: Company Spotlight - ResMed, Inc. - ResMed, Inc. is a key player in the market for sleep-disordered breathing and respiratory disorder treatment products, holding a 3 (Hold) Zacks Rank and a VGM Score of B [11] - The company is particularly appealing to growth investors, with a Growth Style Score of B and a projected year-over-year earnings growth of 22.8% for the current fiscal year [12] - Recent upward revisions in earnings estimates by five analysts for fiscal 2025 have led to an increase in the Zacks Consensus Estimate to $9.48 per share, alongside an average earnings surprise of 4.2% [12]

Company Overview - CONMED Corporation is a major medical products manufacturer specializing in surgical instruments and devices for minimally invasive procedures and monitoring [12] - The company is headquartered in Utica, N.Y., employs approximately 3,600 individuals, and operates several manufacturing facilities [12] Investment Ratings - CONMED has a Zacks Rank of 3 (Hold) with a VGM Score of B, indicating a moderate investment outlook [12] - The company also has a Value Style Score of A, attributed to attractive valuation metrics such as a forward P/E ratio of 12.88, which may appeal to value investors [13] Earnings Estimates - For fiscal 2025, three analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate increasing by $0.07 to $4.42 per share [13] - CONMED has demonstrated an average earnings surprise of 10.4%, suggesting a positive trend in earnings performance [13] Investment Considerations - With a solid Zacks Rank and top-tier Value and VGM Style Scores, CONMED is recommended for investors' consideration [13]

Core Insights - Emerging markets are crucial for Boston Scientific Corporation's (BSX) growth strategy, with a 9.8% year-over-year operational sales growth in Q1 2025 despite geopolitical challenges [1][8] - The medical device industry is experiencing strong growth opportunities in emerging markets, driven by trends such as preventive healthcare and digital health adoption [2] - Boston Scientific's sustained investment and localized strategies position it well to capture future growth in these high-potential regions [3] Emerging Market Performance - BSX's emerging market operations delivered robust sales growth of approximately 9.8% year over year in Q1 2025, supported by favorable economic trends and expanding healthcare infrastructure [1][8] - India’s medical device market is projected to grow from $15.35 billion in 2023 to $20.51 billion by 2029, reflecting a CAGR of 5.35% [2] - China and Brazil are highlighted as key markets due to their large populations and expanding economies, with Southeast Asian countries also gaining importance [2] Competitive Landscape - Competition in emerging markets is intense, with Abbott Laboratories and Medtronic actively expanding their global reach [4] - Abbott's Established Pharmaceuticals Division, focused on emerging markets, reported high single-digit organic growth in Q1 2025, driven by strong demand across Asia, Latin America, and the Middle East [5] - Medtronic generated nearly 49% of its revenues from international markets, with mid-single-digit growth in its emerging market business, particularly in India and Southeast Asia [6] Financial Performance - BSX shares have increased by 35.8% over the past year, outperforming the industry growth of 9.6% and the S&P 500's growth of 12.2% [7][8] - The company trades at a forward price-to-earnings ratio of 33.69, which is above the industry average of 21.73 [9] - The Zacks Consensus Estimate for BSX's earnings has been rising, indicating positive sentiment among analysts [10]

Core Insights - Hologic is experiencing a decline in its Breast Health segment, with sales falling 6.2% in Q2 of fiscal 2025 due to weaker capital equipment sales, following a 2.1% drop in the previous quarter [1][7] - The company holds nearly 80% of the U.S. market share with its 3D Genius mammography machine, and recurring service revenues grew 12% year over year in Q2, indicating a strong contribution from its installed base [2][7] - Hologic's management is optimistic about a growth rebound in Q4 and plans to launch the FDA-cleared Envision mammography platform in fiscal 2026 [7] Financial Performance - Hologic's shares have dropped 12.6% year to date, which is steeper than the industry's decline of 9.8% [6] - The Zacks Consensus Estimate for Hologic's earnings for fiscal 2025 and 2026 has been revised downward over the past 90 days [9] Competitive Landscape - GE Healthcare, a key competitor, reported record double-digit order growth in Q1 of 2025, with organic imaging revenues increasing by 5% year over year [4] - Becton, Dickinson and Company (BD) is also a significant player in the breast biopsy device market, expecting stronger growth in the second half of fiscal 2025 [5] Valuation Metrics - Hologic trades at a forward 12-month earnings multiple of 14.02X, compared to the industry average of 28.64X, indicating a relatively lower valuation [8]

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR SystemsSouthlake, TX, June 04, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focused on advancing the capabilities of ECGs/EKGs for the earlier detection of heart disease, today announced that the U.S. Food and Drug Admin ...

Establishment Labs Holdings (ESTA) 2025 Conference June 04, 2025 07:35 AM ET Speaker0 Good morning, everybody. Thanks for joining us here for our first session in the med tech track. I'm Matt Taylor, the US medical supplies and devices analyst here at Jefferies. And I'm joined by the management team on my left here for Establishment Labs. So we have Pete Caldini, who's the CEO, and Raj Denhoy, the CFO. And we'll have about a half hour for moderated q and a. So I always like to start high level, especially f ...